Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alterations in Muscle Tone lll01:11

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bridging the diagnostic gap: Expanding dementia care navigation for timely diagnosis.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Comparing the value of dynamic versus static image-based tests of emotion recognition in neurodegenerative disease.

Journal of neuropsychology·2026
Same author

Neural embedding of frailty in cognitively unimpaired aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Costs associated with delirium among older patients undergoing complex spine surgeries.

Journal of neurosurgery. Spine·2026
Same author

Classifying cognitive status with TabCAT Match and UDS executive function tests.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Unveiling discrepancies in depression detection among persons with dementia: A comparative analysis of caregiver and self-report.

Journal of Alzheimer's disease : JAD·2026
Same journal

Key Considerations in Telestroke Program Management.

Continuum (Minneapolis, Minn.)·2026
Same journal

Neurology's Action Potential: Delivering on the Promise of Brain Health.

Continuum (Minneapolis, Minn.)·2026
Same journal

Erratum.

Continuum (Minneapolis, Minn.)·2026
Same journal

Management of Large Artery Atherosclerosis.

Continuum (Minneapolis, Minn.)·2026
Same journal

Thrombolysis, Thrombectomy, and Antithrombotic Therapy for Acute Ischemic Stroke.

Continuum (Minneapolis, Minn.)·2026
Same journal

Stroke in Children and Younger Adults.

Continuum (Minneapolis, Minn.)·2026
See all related articles

Related Experiment Video

Updated: May 20, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Parkinsonian dementias.

Katherine L Possin, Daniel I Kaufer

    Continuum (Minneapolis, Minn.)
    |July 20, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Parkinsonian dementia syndromes involve motor and cognitive decline. This review covers Lewy body dementias, multiple system atrophies, and other causes, focusing on diagnosis and treatment.

    More Related Videos

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    Related Experiment Videos

    Last Updated: May 20, 2026

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
    06:45

    Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

    Published on: October 4, 2021

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
    05:51

    Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

    Published on: October 14, 2021

    Area of Science:

    • Neurology
    • Neuroscience
    • Pathology

    Background:

    • Parkinsonian dementia syndromes combine motor and cognitive impairments with diverse causes.
    • Lewy body dementias (Parkinson disease dementia, dementia with Lewy bodies) feature α-synuclein intracellular inclusions.
    • Multiple system atrophies (MSAs) present with autonomic and motor signs and α-synuclein glial inclusions.

    Purpose of the Study:

    • To review clinical presentations, differential diagnoses, and therapeutic strategies for synucleinopathies and related parkinsonian dementia syndromes.
    • To differentiate parkinsonian dementias based on underlying pathology, including α-synuclein and tau abnormalities.
    • To explore less common causes such as drug-induced parkinsonism, vascular parkinsonism, and Alzheimer disease with extrapyramidal signs.

    Main Methods:

    • Review of clinical presentations, diagnostic characteristics, and therapeutic approaches.
    • Pathological differentiation based on protein aggregates (α-synuclein, tau).
    • Comparative analysis of distinct parkinsonian dementia syndromes.

    Main Results:

    • Lewy body dementias and MSAs are key α-synucleinopathies.
    • Progressive supranuclear palsy and corticobasal degeneration are distinguished by tau pathology.
    • Differential diagnosis includes vascular, drug-induced, and metabolic causes.

    Conclusions:

    • Accurate diagnosis of parkinsonian dementia syndromes relies on integrating clinical, imaging, and pathological findings.
    • Understanding the distinct molecular pathologies (α-synuclein vs. tau) is crucial for targeted therapies.
    • Comprehensive management strategies are needed for these complex neurodegenerative disorders.